Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.

Lawrence E, Vegvari C, Ower A, Hadjichrysanthou C, De Wolf F, Anderson RM.

J Alzheimers Dis. 2017;59(4):1359-1379. doi: 10.3233/JAD-170261.

2.

Ocular indicators of Alzheimer's: exploring disease in the retina.

Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M.

Acta Neuropathol. 2016 Dec;132(6):767-787. Epub 2016 Sep 19. Review.

3.

Effects of Physical Exercise Combined with Nutritional Supplements on Aging Brain Related Structures and Functions: A Systematic Review.

Schättin A, Baur K, Stutz J, Wolf P, de Bruin ED.

Front Aging Neurosci. 2016 Jul 6;8:161. doi: 10.3389/fnagi.2016.00161. eCollection 2016. Review.

4.

Cross-View Neuroimage Pattern Analysis in Alzheimer's Disease Staging.

Liu S, Cai W, Pujol S, Kikinis R, Feng DD; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2016 Feb 23;8:23. doi: 10.3389/fnagi.2016.00023. eCollection 2016.

5.

Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study.

Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Machulda M, Lowe VJ, Mielke MM, Roberts RO, Gunter JL, Senjem ML, Geda YE, Rocca WA, Petersen RC, Jack CR Jr.

Neurology. 2016 Mar 22;86(12):1128-35. doi: 10.1212/WNL.0000000000002490. Epub 2016 Feb 24.

6.

Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease.

Zeifman LE, Eddy WF, Lopez OL, Kuller LH, Raji C, Thompson PM, Becker JT.

J Alzheimers Dis. 2015;46(1):167-78. doi: 10.3233/JAD-150047.

7.

The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease.

Tang X, Holland D, Dale AM, Younes L, Miller MI; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2015 Jun;36(6):2093-117. doi: 10.1002/hbm.22758. Epub 2015 Feb 3.

8.

Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease.

Younes L, Albert M, Miller MI; BIOCARD Research Team.

Neuroimage Clin. 2014 Apr 21;5:178-87. doi: 10.1016/j.nicl.2014.04.009. eCollection 2014.

9.

Preventing vascular effects on brain injury and cognition late in life: knowns and unknowns.

Carmichael O.

Neuropsychol Rev. 2014 Sep;24(3):371-87. doi: 10.1007/s11065-014-9264-7. Epub 2014 Aug 2. Review.

10.

Sleep duration and age-related changes in brain structure and cognitive performance.

Lo JC, Loh KK, Zheng H, Sim SK, Chee MW.

Sleep. 2014 Jul 1;37(7):1171-8. doi: 10.5665/sleep.3832.

11.

Advances in longitudinal studies of amnestic mild cognitive impairment and Alzheimer's disease based on multi-modal MRI techniques.

Hu Z, Wu L, Jia J, Han Y.

Neurosci Bull. 2014 Apr;30(2):198-206. doi: 10.1007/s12264-013-1407-y. Epub 2014 Feb 27. Review.

12.

Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences.

Mielke MM, Vemuri P, Rocca WA.

Clin Epidemiol. 2014 Jan 8;6:37-48. doi: 10.2147/CLEP.S37929. eCollection 2014. Review.

13.

The diffeomorphometry of temporal lobe structures in preclinical Alzheimer's disease.

Miller MI, Younes L, Ratnanather JT, Brown T, Trinh H, Postell E, Lee DS, Wang MC, Mori S, O'Brien R, Albert M; BIOCARD Research Team.

Neuroimage Clin. 2013 Sep 16;3:352-60. doi: 10.1016/j.nicl.2013.09.001. eCollection 2013.

14.

Early indications of future cognitive decline: stable versus declining controls.

Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M.

PLoS One. 2013 Sep 9;8(9):e74062. doi: 10.1371/journal.pone.0074062. eCollection 2013.

15.

Traumatic brain injury, neuroimaging, and neurodegeneration.

Bigler ED.

Front Hum Neurosci. 2013 Aug 6;7:395. doi: 10.3389/fnhum.2013.00395. eCollection 2013.

16.

Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.

Perrin RJ, Payton JE, Malone JP, Gilmore P, Davis AE, Xiong C, Fagan AM, Townsend RR, Holtzman DM.

PLoS One. 2013 May 20;8(5):e64314. doi: 10.1371/journal.pone.0064314. Print 2013.

17.

Neuropathologic basis of age-associated brain atrophy.

Erten-Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB, Kramer P, Kaye JA.

JAMA Neurol. 2013 May;70(5):616-22. doi: 10.1001/jamaneurol.2013.1957.

18.

Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.

Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY, Dalaker TO, Kurz MW, Larsen JP, Somme JH, Thompson PM, Tysnes OB, Apostolova LG.

Mov Disord. 2013 Mar;28(3):302-10. doi: 10.1002/mds.25282. Epub 2013 Feb 13.

19.

Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.

Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2013 Feb 12;80(7):648-54. doi: 10.1212/WNL.0b013e318281ccd3. Epub 2013 Jan 9.

20.

The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease.

Ritchie CW, Ritchie K.

BMJ Open. 2012 Nov 19;2(6). pii: e001893. doi: 10.1136/bmjopen-2012-001893. Print 2012.

Supplemental Content

Support Center